Loading…
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Legislative Progress
Introduced
January 17, 2023
Latest Action
January 27, 2023
Primary Sponsor
Diana HarshbargerRepublican(TN)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
69pct
10d open
vs 10,564 other HR bills in the 118th — cohort avg 68d
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2023 · first_quarter · Medical/Disease Research/Clinical Labs
H.R. 427, S. 95 Support and Value Expectant Moms and Babies Act; H.R. 398 Protecting Life and Integrity Research Act; H.R. 1466 Safe RESEARCH Act; H.R. 383 Nullify FDA REMS change; H.R. 632, S. 15 Ensuring Accurate and Complete Abortion Data Reporting Act of 2023.
Client expense: $300,000 · Firm income: Not reported
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Family issues/Abortion/Adoption
Equal Rights Amendment; Protecting Pain-Capable Unborn Child from Late-Term Abortions; H.R. 12, S. 701 Womens Health Protection Act of 2023; H.R. 26, S. 204 Born-Alive Abortion Survivors Protection Act; H.R. 792, S.78 Child Interstate Abortion Notification Act; Veterans Affairs Reproductive Health Services Interim Final Rule; S. 74 Providing for Life Act; H.R. 175 Heartbeat Protection Act of 2023; H.R. 427, S. 95 Support and Value Expectant Moms and Babies Act; Chemical abortion; Congressional Actions against pro-abortion political violence; H.R. 279 Pharmacist Conscience Protection Act; H.R. 1771 Pregnancy Resource Center Defense Act; H.R. 384 Protecting Life from Chemical Abortions Act; H.R. 1297 To amend title 10, United States Code, to restrict the Secretary of Defense from paying or reimbursing expenses relating to abortion services; H.R. 7, S. 62 No Taxpayer Funding for Abortion Act and Abortion Insurance Full Disclosure Act of 2023; H.R. 398 Protecting Life and Integrity Research Act; H.R. 471, S. 1074 Women's Public Health and Safety Act; H.Con.Res. 3 Expressing the sense of the House of Representatives condemning the recent attacks on pro-life facilities, groups, and churches; H.R. 461, S.18 Protect Individuals with Down Syndrome from Selective Abortion Act; S.959 Stopping Traffickers and Their Accomplices Act; H.R. 437 Reporting Accountability and Abuse Prevention Act; H.R. Resolution 48 Resolution expressing support for the Dobbs decision; H.R. 416 Prohibiting Abortion Industrys Lucrative Loopholes Act; H.R. 383 Nullify FDA REMS change; H.R. 421 Teleabortion Prevention Act; H.R. 435 Protecting Life on College Campus Act of 2023; S.Res. 10, H.Res. 52 Day of Tears Resolution; S.76, H.R. 517 Standing with Moms Act; S. 166 HEALING Mothers and Fathers Act; H.R. 862 Dismemberment Abortion Ban Act; H.R. 632, S. 15 Ensuring Accurate and Complete Abortion Data Reporting Act of 2023; S. 197 American Values Act; H.R. 983 Second Chance at Life Act; H.R. 1470 No Federal Funds for Abortion Travel Expenses Act; H.R. 1126 HOPE Act; S. 1102 Dignity for Aborted Children Act; S. 822 Modification to Department of Defense Travel Authorities for Abortion-Related Expenses Act; Holds on DOD confirmations and promotions.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2023 · first_quarter · Pharmacy
H.R. 427, S. 95 Support and Value Expectant Moms and Babies Act; Chemical abortion; H.R. 279 Pharmacist Conscience Protection Act; H.R. 384 Protecting Life from Chemical Abortions Act; H.R. 383 Nullify FDA REMS change;
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2023 · first_quarter · Health Issues
H.R. 384; Protecting Life from Chemical Abortions Act, Require the FDA to reinstate in person dispensing for chemical abortion H.R. 383; A bill to nullify modifications made by the FDA to the risk evaluation and mitigation strategy for the abortion pill, Reinstating prior REMS protocol for chemical abortion
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2023 · first_quarter · Health Issues
Endorsed, strategized, supported advancement of H.R.734, the Protection of Women and Girls in Sports Act Endorsed, strategized, supported advancement of S.816, the Protection of Women and Girls in Sports Act Opposed an allocation of CDC grant, "93.391: Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises" Supported Senate Pro-Life Caucus Membership Opposed S.754 (117th) - Ensuring Lasting Smiles Act Supported oversight question for the record about FDA-Certified Abortion Pill Dispensaries on College Campuses Supported oversight question for the record about FDA protocol on establishing regulation over drug manufacturers for drugs to induce abortions Supported oversight question for the record about U.S. Department of Health and Human Services' policy for the Protection of Human Subjects 45 CFR 46 Endorsed H.R.6060 (117th) Conscience Protection Act Endorsed congressional letter to the Food and Drug Administration calling on the administration to safeguard women and childrens health by rescinding its abortion pill regulations Endorsed S.750 - No Taxpayer Funding for Health Centers Providing Abortion Act Endorsed H.R.383- to nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes Endorsed congressional letter to FDA Commissioner Robert Califf, M.D., explaining the policy and legal faults in the FDA decision to approve chemical abortion drugs and then further eliminate the in-person dispensing in an attempt to make abortion drugs available by mail Endorsed S.13 - Protect Funding for Womens Health Care Act Endorsed S.95 - SAVE Moms and Babies Act Endorsed H.R.427 - SAVE Moms and Babies Act Endorsed congressional letter to Secretary of U.S. Department of Health and Human Services Xavier Becerra on oversight of pediatric "gender affirming care" Endorsed S.76 - Standing With Moms Act Endorsed H.R.517 - Standing With Moms Act Endorsed H.R.1074 - Women's Public Health and Safety Act Endorsed S.471 - Women's Public Health and Safety Act Endorsed bicameral comment letter against the elimination of the moral exemptions to the contraceptive mandate regulation Endorsed S.565 - Pregnancy Center Security Act Endorsed H.R.384 - Protecting Life From Chemical Abortions Act
Client expense: $15,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Republican |
| LA |
| Daniel Webster | Republican | FL |
| Doug Lamborn | Republican | CO |
| Earl L. "Buddy" Carter | Republican | GA |
| Glenn Grothman | Republican | WI |
| James R. Baird | Republican | IN |
| Jeff Duncan | Republican | SC |
| Jim Banks | Republican | IN |
| John R. Moolenaar | Republican | MI |
| Kevin Hern | Republican | OK |
| Lauren Boebert | Republican | CO |
| Mary E. Miller | Republican | IL |
| Michael Guest | Republican | MS |
| Mike Bost | Republican | IL |
| Mike Flood | Republican | NE |
| Paul A. Gosar | Republican | AZ |
| Pete Sessions | Republican | TX |
| Randy Feenstra | Republican | IA |
| Randy K. Weber, Sr. | Republican | TX |
| Robert B. Aderholt | Republican | AL |
| Ronny Jackson | Republican | TX |
| Rudy Yakym III | Republican | IN |
| Tony Gonzales | Republican | TX |